Abstract
Background
Shifts in pneumococcal serotypes following introduction of 7-valent pneumococcal conjugate vaccine (PCV-7) may alter the presence of other bacterial pathogens co-inhabiting the same nasopharyngeal niche.
Methodology/Principal Findings
Nasopharyngeal prevalence rates of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis were investigated before, 3 and 4.5 years after introduction of PCV-7 in the national immunisation program in children at 11 and 24 months of age, and parents of 24-month-old children (n≈330/group) using conventional culture methods. Despite a virtual disappearance of PCV-7 serotypes over time, similar overall pneumococcal rates were observed in all age groups, except for a significant reduction in the 11-month-old group (adjusted Odds Ratio after 4.5 years 0.48, 95% Confidence Interval 0.34–0.67). Before, 3 and 4.5 years after PCV-7 implementation, prevalence rates of S. aureus were 5%, 9% and 14% at 11 months of age (3.59, 1.90–6.79) and 20%, 32% and 34% in parents (1.96, 1.36–2.83), but remained similar at 24 months of age, respectively. Prevalence rates of H. influenzae were 46%, 65% and 65% at 11 months (2.22, 1.58–3.13), 52%, 73% and 76% at 24 months of age (2.68, 1.88–3.82) and 23%, 30% and 40% in parents (2.26, 1.58–3.33), respectively. No consistent changes in M. catarrhalis carriage rates were observed over time.
Conclusions/Significance
In addition to large shifts in pneumococcal serotypes, persistently higher nasopharyngeal prevalence rates of S. aureus and H. influenzae were observed among young children and their parents after PCV-7 implementation. These findings may have implications for disease incidence and antibiotic treatment in the post-PCV era.
Introduction
The 7-valent pneumococcal conjugate vaccine (PCV-7; Prevenar™, Pfizer) prevents nasopharyngeal acquisition of 7 paediatric serotypes in children and transmission to others [1], [2]. This results in protection against PCV-7 serotype disease in all age groups [3]–[5]. The vacant nasopharyngeal niche in PCV-7 vaccinated children is immediately occupied by non-PCV-7 serotype pneumococci either due to true replacement, unmasking, or capsular switch, resulting in similar overall pneumococcal carriage rates [1].
Previous reports have demonstrated potential associations between pneumococcal presence in the nasopharynx, in particular vaccine serotypes, and bacteria like H. influenzae, M. catarrhalis or S. aureus co-inhabiting the same ecological niche [6]–[8]. This has raised the concern that shifts in pneumococcal serotypes after PCV-7 vaccination may facilitate the involvement of other major contributors to respiratory, as demonstrated in three otitis media efficacy trials [9]–[11], or invasive disease in childhood [12]–[14]. A temporary increase in S. aureus nasopharyngeal carriage at one year of age after PCV-7 vaccinations at 2, 4 and 11 months was previously reported in a randomized controlled trial [15]. Several years of nationwide PCV-7 vaccine pressure might enhance shifts in the bacterial ecosystem in infants. Young children are an important reservoir and major source of transmission of bacteria to the whole community [14], [16], [17]. Therefore, the aim of this study was to investigate the long-term effects of PCV-7 on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis in healthy PCV-7 vaccinated children and their unvaccinated parents in the Netherlands.
Methods
Ethics statement
Both cross-sectional studies were approved by an acknowledged independent ethics committee from the Netherlands (CCMO; Centrale Commissie Mensgebonden Onderzoek, available at: http://www.ccmo-omline.nl). Parents of children living in the western part of the Netherlands were provided with written information about the study and asked to participate. Written informed consent was obtained from all parents and the procedures followed were in accordance with European Statements for Good Clinical Practice and the Declaration of Helsinki of the World Medical Association.
Study design
PCV-7 was implemented in the national immunization program (NIP) for all infants born after 31 March 2006 at 2, 3, 4 and 11 months of age without a catch-up campaign for older children. Traditionally, PCV-7 vaccine uptake reached almost 95% [18]. Two subsequent cross-sectional carriage studies of similar design were conducted to evaluate nasopharyngeal bacterial carriage after introduction of PCV-7 in the national immunization program (NIP): 1) 3 years post-PCV-7 (February through July 2009) and 2) 4.5 years post-PCV-7 (September 2010 through January 2011). In both cross-sectional carriage studies, nasopharyngeal bacterial carriage was evaluated by means of home visits in two age-cohorts of healthy children vaccinated according to the Dutch NIP: 1) 11-month-old children after 3 primary doses but who had not yet, or had within the last week, obtained the booster dose at 11 months, and 2) 24-month-old children after four doses. Additionally, nasopharyngeal samples were collected from one of the parents of each 24-month-old child. Exclusion criteria were known or suspected immunodeficiency, craniofacial or chromosomal abnormalities, coagulation disorders and use of anticoagulant medication. Data of the vaccinated children cohorts and their parents were compared with data from PCV-7 unvaccinated children at the age of 12 and 24 months and parents of 24-month-old children derived from a previous, randomized controlled trial that had started in the Netherlands well before national PCV7 implementation for infants (NCT00189020) [19]. In this trial, children had been included at the age of 6 weeks between July 2005 and February 2006 and were followed-up until 24 months of age.
Procedures
Transnasal nasopharyngeal samples were obtained from children and parents by trained study personnel with a nylon flocked flexible sterile Copan E-swab according to World Health Organization standard procedures [20]. From parents, an additional transoral nasopharyngeal sample was collected with a rigid sterile swab under direct observation of the posterior pharynx, as the pneumococcal yield is known to be higher in adults when taking both samples [21]. After sampling, all swabs were directly inoculated in liquid Amies medium and plated within 24 hours. All the swabs of the three studies were processed by same laboratory and cultured for presence of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis according to standard bacteriological procedures for conventional culture. One pneumococcal colony per plate was subcultured and serotyped by Quellung reaction using type-specific antisera from the Statens Serum Institute (Copenhagen, Denmark). In a post-hoc analysis, the presence of methicillin resistance was determined in a random sample of 30 (65%) of the S. aureus strains obtained from children at 11 months of age 4.5 years after PCV-7 implementation by using disk diffusion method for cefoxitine and by detection of the mecA gene [22].
Covariates
Parents of the participating children completed a brief survey on the following possible predictors of nasopharyngeal bacterial carriage: age, sex, season of sampling, antibiotic use within one month prior to sampling, symptoms of a respiratory tract infection and/or acute otitis media during sampling, presence of siblings in the household, day care attendance of the participating child, passive smoke exposure indoors, active smoking of the participating parent.
Statistical analyses
This study was designed to demonstrate changes in pneumococcal carriage after PCV-7 implementation requiring 330 persons per group as described previously (4). Assessment of the effects of PCV-7 on carriage of H. influenzae, M. catarrhalis and S. aureus were designated secondary outcomes. Given estimated prevalence rates of 49%, 64% and 5% for H. influenzae, M. catarrhalis and S. aureus in children based on previous reports [13], [20], a sample size of 330 could detect with 80% power and a 2-sided α of 0.05 an increase of 10%, 9% and 6%, respectively. Differences in prevalence rates were tested using 2-sided χ2 or Fisher's exact test, where appropriate. P-values <0.05 were considered significant. Multivariate analysis with backward LR binary logistic regression modelling was used to obtain adjusted estimates of the association between the outcomes and intervention as given by adjusted odds ratio's (aOR) and their corresponding 95% confidence intervals (95% CI). All measured possible confounders were entered in this model and removed when p-value was >0.10. To obtain the aOR for the intervention effect in case the intervention variable was not included in the final model (i.e. p-value >0.10), this variable combined with all remaining variables of the final backward LR model were entered in a binary logistic regression model without selection (SPSS version 17.0).
Results
Baseline characteristics of children and their parents before, 3 and 4.5 years after implementation of PCV-7 in the NIP are shown in Table 1. The most noticeable difference among all three time-points is the season of sampling.
Table 1. Characteristics of children and their parents before, 3 and 4.5 years after implementation of PCV-7 in the Netherlands.
| 11 months | 24 months | ||||||
| Pre-PCV7 | 3yr Post | 4.5yr Post | Pre-PCV7 | 3yr Post | 4.5yr Post | ||
| no. (%) | no. (%) | no. (%) | no. (%) | no. (%) | no. (%) | ||
| Children | n = 319 | n = 329 | n = 330 | n = 321 | n = 330 | n = 330 | |
| Male sex | 156 (49) | 181 (55) | 173 (52) | 155 (48) | 187 (57) | 171 (52) | |
| Mean age in months (SD) | 12.0 (0.3) | 10.9 (0.3) | 10.7 (0.4) | 24.2 (0.6) | 24.0 (0.3) | 23.8 (0.5) | |
| Presence of siblings <5yr | 126 (40) | 84 (26) | 145 (44) | 127 (40) | 135 (41) | 154 (47) | |
| Day care attendancea | 208 (65) | 226 (69) | 222 (67) | 224 (70) | 233 (71) | 259 (79) | |
| Passive smoke exposureb | 21 (7) | 5 (2) | 9 (3) | 26 (8) | 16 (5) | 12 (4) | |
| Signs of URTI and/or OMAc | 95 (30) | 95 (29) | 112 (34) | 82 (26) | 69 (21) | 114 (35) | |
| Antimicrobial drug used | 20 (6) | 24 (7) | 27 (8) | 10 (3) | 23 (7) | 15 (5) | |
| Period of sampling: | |||||||
| October-March | 149 (47) | 82 (25) | 274 (83) | 156 (48) | 299 (91) | 299 (91) | |
| April-September | 170 (53) | 247 (75) | 56 (17) | 166 (52) | 31 (9) | 31 (9) | |
| Pre-PCV7 | 3yr Post | 4.5yr Post | |||||
| Parents | n = 296 | n = 324 | n = 326 | ||||
| Male sex | 51 (17) | 53 (16) | 58 (18) | ||||
| Mean age in years (SD) | 34.7 (4.9) | 35.1 (4.4) | 35.3 (4.5) | ||||
| Active smoking | 40 (14) | 34 (11) | 41 (13) | ||||
| Antimicrobial drug used | 9 (3) | 20 (6) | 16 (5) | ||||
Note. PCV-7; 7-valent pneumococcal conjugate vaccine. SD; standard deviation. aDefined as more than 4 hours per week with at least 1 child from a different household. bDefined as passive tobacco smoke exposure indoors at least ≥1 cigar or cigarette during ≥5 days/week. cThe presence of symptoms of an upper respiratory tract infection (URTI) and/or acute otitis media (OMA) as defined by evaluation of parents. dDefined as use of oral or intravenous antibiotics within 1 month before sample was taken.
Carriage of S. pneumoniae
Three years after PCV-7 implementation (post-PCV7), a nearly complete eradication of PCV-7 serotype carriage in children and adults was demonstrated, resulting in significant declines in overall pneumococcal carriage at 11 and 24 months of age and similar carriage rates in parents [2]. After 4.5 years, PCV-7-serotypes as well as cross-reactive serotype 6A were found only incidentally in all age groups (Table S1). Compared to pre-PCV7, overall pneumococcal prevalence rates had remained significantly lower at 11 months of age after 4.5 years (adjusted Odds Ratio (aOR) 0.48, 95% Confidence Interval 0.34–0.67), but had risen to similar levels at 24 months of age and in parents (Table 2). Serotype 19A became the predominant colonizer in all age groups, followed by serotypes 6C, 15 B/C and 11A (Table S1).
Table 2. Frequencies of nasopharyngeal carriage and (adjusted) odds ratios of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis in children and parents before, 3 and 4.5 years after PCV-7 implementation.
| Pre-PCV7 | 3yr Post | 4.5yr Post | 3yr Post vs. Pre-PCV7 | 4.5yr Post vs. Pre PCV7 | 4.5yr Post vs. 3yr Post PCV7 | ||||
| no. (%) | no. (%) | no. (%) | OR (95% CI) | aOR (95% CI) | OR (95% CI) | aOR (95% CI) | OR (95% CI) | aOR (95% CI) | |
| 11 monthsa: | n = 319 | n = 329 | n = 330 | ||||||
| S. pneumoniae | 214 (67) | 154 (47) | 173 (52) | 0.43 (0.31–0.59) | 0.43 (0.30–0.60) | 0.54 (0.39–0.74) | 0.48 (0.34–0.67) | 1.25 (0.92–1.70) | 1.10 (0.79–1.53) |
| PCV-7-serotypes | 122 (38) | 25 (8) | 10 (3) | 0.13 (0.08–0.21) | 0.14 (0.09–0.23) | 0.05 (0.03–0.10) | 0.04 (0.02–0.08) | 0.38 (0.18–0.80) | 0.32 (0.15–0.69) |
| Non-PCV-7- serotypes | 92 (29) | 129 (39) | 166 (50) | 1.59 (1.15–2.21) | 1.75 (1.24–2.46) | 2.50 (1.81–3.46) | 2.59 (1.85–3.62) | 1.57 (1.15–2.14) | 1.47 (1.05–2.05) |
| S. aureus | 16 (5) | 31 (9) | 46 (14) | 1.97 (1.06–3.68) | 1.97 (1.04–3.72) | 3.07 (1.70–5.54) | 3.59 (1.90–6.79) | 1.56 (0.96–2.53) | 1.88 (1.14–3.13) |
| H. influenzae | 146 (46) | 212 (64) | 213 (65) | 2.15 (1.57–2.94) | 2.69 (1.90–3.80) | 2.16 (1.57–2.96) | 2.22 (1.58–3.13) | 1.01 (0.73–1.38) | 0.83 (0.59–1.17) |
| M. catarrhalis | 218 (68) | 210 (64) | 251 (76) | 0.82 (0.59–1.13) | 0.89 (0.62–1.27) | 1.47 (1.04–2.08) | 1.25 (0.85–1.83) | 1.80 (1.28–2.53) | 1.82 (1.27–2.61) |
| 24 monthsa: | n = 321 | n = 330 | n = 330 | ||||||
| S. pneumoniae | 211 (66) | 162 (49) | 211 (64) | 0.50 (0.37–0.69) | 0.50 (0.36–0.70) | 0.92 (0.67–1.28) | 0.81 (0.58–1.13) | 1.84 (1.35–2.51) | 1.73 (1.26–2.38) |
| PCV-7-serotypes | 114 (36) | 14 (4) | 11 (3) | 0.08 (0.05–0.14) | 0.08 (0.05–0.15) | 0.06 (0.03–0.12) | 0.06 (0.03–0.12) | 0.78 (0.35–1.74) | 0.76 (0.34–1.70) |
| Non-PCV-7- serotypes | 97 (30) | 148 (45) | 200 (61) | 1.88 (1.36–2.59) | 1.99 (1.43–2.77) | 3.55 (2.57–4.92) | 3.35 (2.40–4.67) | 1.89 (1.39–2.58) | 1.78 (1.30–2.44) |
| S. aureus | 18 (6) | 25 (8) | 24 (7) | 1.38 (0.74–2.58) | 1.39 (0.74–2.63) | 1.32 (0.70–2.48) | 1.61 (0.84–3.07) | 0.96 (0.54–1.71) | 1.09 (0.60–1.97) |
| H. influenzae | 168 (52) | 240 (73) | 252 (76) | 2.43 (1.75–3.37) | 2.70 (1.91–3.82) | 2.94 (2.10–4.12) | 2.68 (1.88–3.82) | 1.21 (0.85–1.72) | 0.99 (0.68–1.44) |
| M. catarrhalis | 189 (59) | 199 (60) | 264 (80) | 1.06 (0.78–1.45) | 1.37 (0.97–1.94) | 2.84 (2.00–4.03) | 1.75 (1.18–2.61) | 2.67 (1.89–3.79) | 1.37 (0.85–2.21) |
| Parentsb: | n = 296 | n = 324 | n = 326 | ||||||
| S. pneumoniae | 50 (17) | 51 (16) | 66 (20) | 0.92 (0.60–1.41) | 0.91 (0.59–1.40) | 1.25 (0.83–1.88) | 1.22 (0.81–1.84) | 1.36 (0.91–2.03) | 1.33 (0.89–2.00) |
| PCV-7-serotypes | 25 (8) | 2 (1) | 7 (2) | 0.07 (0.02–0.29) | 0.07 (0.02–0.29) | 0.24 (0.10–0.56) | 0.24 (0.10–0.55) | 3.53 (0.73–17.14) | 4.09 (0.83–20.05) |
| Non-PCV-7- serotypes | 25 (8) | 49 (15) | 59 (18) | 1.93 (1.16–3.22) | 1.93 (1.16–3.23) | 2.50 (1.52–4.10) | 2.43 (1.48–4.00) | 1.29 (0.86–1.95) | 1.25 (0.82–1.89) |
| S. aureus | 60 (20) | 104 (32) | 111 (34) | 1.86 (1.29–2.68) | 1.85 (1.36–2.83) | 2.03 (1.41–2.92) | 1.96 (1.36–2.83) | 1.09 (0.79–1.51) | 1.07 (0.77–1.49) |
| H. influenzae | 67 (23) | 96 (30) | 130 (40) | 1.44 (1.00–2.07) | 1.49 (1.03–2.14) | 2.27 (1.60–3.22) | 2.26 (1.58–3.33) | 1.58 (1.14–2.18) | 1.52 (1.10-2.11) |
| M. catarrhalis | 28 (10) | 43 (13) | 71 (22) | 1.47 (0.88–2.43) | 1.44 (0.87–2.39) | 2.67 (1.67–4.26) | 2.54 (1.59–4.08) | 1.82 (1.20–2.76) | 1.77 (1.17–2.69) |
Note. PCV-7; all serotypes included in 7-valent pneumococcal conjugate vaccine. Non-PCV-7; all other serotypes not included in 7-valent pneumococcal conjugate vaccine. OR; odds ratio.CI; confidence interval. aOR; adjusted odds ratio. All (a)OR-values are based on comparison with cohort as indicated. aIn children, OR-values were adjusted by multivariate analysis for sex, months of sampling, presence of siblings <5yr in the household, day care attendance, antibiotic use, passive smoke exposure and the presence of URTI and/or OMA using binary logistic regression with backward LR. bIn parents, OR-values were adjusted by multivariate analysis for sex, months of sampling, antibiotic use, active smoking, presence of siblings <5yr other than participating child and day care attendance of their participating child.
Carriage of S. aureus
The prevalence of S. aureus was significantly higher in children at 11 months of age (aOR 1.97, 1.04–3.72) and in parents (1.85, 1.36–2.83) 3 years post-PCV7 compared to pre-PCV7. After 4.5 years, a further increase in the prevalence of S. aureus was observed at 11 months of age (2.26, 1.58–3.33) compared to pre-PCV7 and results persisted in parents. No changes in S. aureus carriage were observed in children at 24 months of age after 3 and 4.5 years post-PCV7 (Table 2).No methicillin resistance was detected in tested isolates (n = 30) obtained from 11-month-old children 4.5 years post-PCV-7.
Carriage of H. influenzae
The prevalence of H. influenzae was significantly higher in children at 11 months (aOR 2.69, 1.90–3.80), 24 months of age (2.70, 1.91–3.82) and parents (1.49, 1.03–2.14) after 3 years of PCV-7 implementation compared to pre-PCV7. After 4.5 years, higher levels persisted in children, and a further increase in prevalence of H. influenzae was observed in parents (2.26, 1.58–3.33) compared to pre-PCV7 (Table 2).
Carriage of M. catarrhalis
The prevalence of M. catarrhalis remained unchanged in children and parents 3 years post-PCV7 as compared to pre-PCV7. After 4.5 years, the prevalence of M. catarrhalis remained similar at 11 months of age, but was significantly higher in children at 24 months of age (aOR 1.75, 1.18–2.61) and in parents (2.54, 1.59–4.08) compared to pre-PCV7 (Table 2).
Discussion
This is the first study that describes the long-term follow-up of nasopharyngeal carriage of S. aureus, H. influenzae and M. catarrhalis next to S. pneumoniae after introduction of PCV-7 in the NIP. In addition to the virtual elimination of PCV-7 serotypes, we demonstrated significantly higher S. aureus carriage rates in children by the end of the first year of life and in the parents group. For H. influenzae, significantly higher prevalence rates were detected among children at both 11 and 24 months of age and in parents. Shifts in nasopharyngeal carriage profiles of these bacteria may affect disease incidence due to these pathogens in PCV-7 vaccinated children as well as in the population. Moreover, increased nasopharyngeal carriage may lead to increased exposure of strains to antibiotics, which may subsequently lead to selection of resistant ones [23].
The results on S. aureus carriage are consistent with a previous randomized controlled trial that demonstrated a doubled rate of S. aureus carriage in healthy children at 12 months of age after 2+1 doses of PCV-7 and in parents as compared to unvaccinated controls [15]. Similar to our present study, in this trial the impact of PCV-7 on S. aureus carriage in children was limited to young children around 12 months of age and no longer present at 18 or 24 months of age. This indicates an effect on S. aureus carriage when carriage dynamics are at their peak, around PCV-7 vaccinations in infancy, and disappearing later after non-PCV-7 serotypes have filled in the gap or by age-dependent maturation of the immune system in the second year of life. The impact of pneumococcal vaccinations on S. aureus presence is also in line with a randomized controlled trial where an increased rate of S. aureus culture–positive acute otitis media (AOM) was demonstrated shortly after pneumococcal vaccinations in children suffering from recurrent AOM, who were PCV-7-vaccinated followed by the 23-valent polysaccharide vaccine [11].
In support of these findings, several studies from other sites have also reported a negative interaction between S. pneumoniae, in particular PCV-7-serotypes, and S. aureus carriage in healthy children [6]–[8], [24] but also during severe pneumonia illness in HIV-negative children [25]. In contrast to these studies, two observational studies performed after introduction of PCV-7, one in children with acute otitis media and one in primary-care visiting children, did not yield an effect on S. aureus nasopharyngeal carriage [26], [27]. However, these studies included children from various age groups with different intervals between pneumococcal vaccinations and the sampling moment, and may not have detected the temporal impact of PCV-7 on S. aureus carriage around vaccinations in infancy. Furthermore, no comparison to a baseline level of S. aureus carriage before PCV-7 implementation could be made and several methodological concerns were raised [28].
One possible mechanism of interaction between vaccine serotype pneumococci and S. aureus is the presence of pneumococcal pilus predicting the absence of S. aureus carriage in pneumococcal carriers [29]. Host immunological factors may also play a role, as the negative interaction between S. pneumoniae and S. aureus is not reported in HIV-positive children [25]. No negative interaction between S. pneumoniae and S. aureus has been identified in adults. Although we cannot discriminate the route of intra-familial transmission in this cross-sectional study, we therefore hypothesize that vaccinated children induce more transmission of S. aureus to parents who become colonized for longer periods. Persistent carriage, as defined by continuous colonisation by the same strain of S. aureus in time, is a common phenomenon in adults but rarely detected in infants [8], [30].
The observed increase in nasopharyngeal carriage of S. aureus is worrisome as this is a known risk factor for infection [14], [31], and especially young children in first year of life are vulnerable for S. aureus disease [32]. In the last decade, only few population-based studies have been published on invasive S. aureus disease (ISD) after the introduction of PCV-7. Of those, two large studies from the USA reported a significant absolute increase in ISD, which could solely be attributed to an increase in MRSA [33], [34] and no other countries have reported substantial increases so far. Based on our results, long-term follow-up of staphylococcal carriage and ISD surveillance, especially after complete eradication of pneumococcal vaccine serotypes and following implementation of broader-coverage pneumococcal conjugate vaccines in the population, needs to be implemented.
The long-term impact of PCV-7 implementation on nasopharyngeal carriage of H. influenzae and M. catarrhalis was also investigated. Two Finnish otitis media trials investigating a CRM197- or a OMPC-protein based PCV-7 in healthy infants noted an increase in either H. influenzae or M. catarrhalis in middle-ear fluid during episodes of AOM, respectively [9], [10]. Post-marketing observational studies in the USA reported relative increases in both H. influenzae and M. catarrhalis causing AOM in children after PCV-7 implementation [35], [36].
Relatively high nasopharyngeal carriage rates of H. influenzae and M. catarrhalis were already observed before PCV-7 introduction in the Netherlands [37]. Nevertheless, we observed significant increases in H. influenzae carriage in children of both age groups as well in their parents both 3 and 4.5 years after introduction of PCV-7. Although no consistent changes in nasopharyngeal carriage of H. influenzae were observed by conventional culture techniques in a previous randomized controlled trial evaluating reduced-dose schedules of PCV-7 [37], a trend towards increased presence and abundance of Haemophilus species by molecular techniques was observed in PCV-7 vaccinated children compared with PCV-7 unvaccinated controls after 2+1 doses of PCV-7 (unpublished data). We therefore hypothesize that implementation of a full-dose schedule with 4 doses of PCV-7, together with continuing nationwide PCV-7 vaccine pressure, may have facilitated increased H. influenzae carriage in our study. In this study, we have not typed the recovered H. influenzae isolates. However, between 2008 and 2010, during the same period as the current study, we conducted a large randomized controlled trial in the same area in the Netherlands in which 780 infants were vaccinated with either CRM197-conjugated PCV-7 or Protein-D-conjugated PCV-10 with carriage of H. influenzae as endpoint. Similar to the present study, 65% of all cultured swabs were positive for H. influenzae based on conventional culture methods. After discrimination from H. haemolyticus by PCR, 92% were confirmed as H. influenzae. Of these, 8% were encapsulated strains; most frequently type a (5%) and f (1%) (unpublished data).
As for M. catarrhalis, no consistent changes in carriage after PCV-7 implementation were found, except for an increase in carriage in 24-month-old children and their parents 4.5 years post-PCV7. These results are in line with the randomized controlled trial which found no changes in M. catarrhalis carriage [37]. Again, bacterial interference, resource availability and host immunological factors may all play a role in the co-existence or competition between species in the nasopharynx, but the exact mechanisms of interactions are not yet fully elucidated [38].
With respect to the pneumococcal carriage surveillance study 4.5 years after PCV-7 introduction, we found that PCV-7-serotype pneumococci and cross-reactive serotype 6A were virtually eliminated among children and their parents. Simultaneously, non-PCV-7-serotypes increased significantly and showed higher diversity. Consistent with reports from other countries, 19A became the most predominant colonizing serotype in all investigated age groups in the Netherlands, followed by 6C, 15B/C and 11A [39], [40]. Also in IPD, serotype 19A has increased significantly to become the fourth most frequently isolated serotype in the Netherlands after 7F, 1 and 8. Although frequently carried serotypes 6C, 15B/C and 11A are now also more frequently found in IPD, their total number of cases still remained low (unpublished data). However, due to the adaptive nature of the pneumococcus [41], long-term nasopharyngeal carriage and IPD surveillance in all age groups remain essential to evaluate health and economic impact in the future.
A limitation of the current observational study design is that we documented associations and no causalities between the introduction of PCV-7 and changes in nasopharyngeal bacterial carriage patterns. However, after correction for differences in measured potential confounders by using multivariate analysis, our results remained robust. Nonetheless, the impact of other unmeasured determinants such as the presence of viruses or climatologic factors cannot be excluded. Also, our results for S. aureus may have been underestimated due to sampling the nasopharyngeal niche rather than sampling the anterior nares, which is assumed the ecological site for S. aureus [14].
Strengths of our study are the consistency of our data measured in large cohorts at two sequential time points after PCV-7 implementation and compared to a historical baseline. Importantly, similar standard operating procedures were followed in the same laboratory for all three studies. Furthermore, we evaluated the impact of PCV-7 not only in vaccinated infants but also in unvaccinated adult contacts in a country with PCV-7 uptake of almost 95% in the NIP [18]. Finally, the studies were performed in a country with low antibiotic consumption and resistance rates and therefore unlikely to be confounded by antibiotic resistant clones [42].
In conclusion, next to large shifts in pneumococcal serotypes, we observed persistently higher carriage rates of S. aureus and H. influenzae after PCV-7 implementation in children at a young age vulnerable for bacterial infections as well as in parents. In addition to the need for ongoing surveillance of nasopharyngeal bacterial carriage over time, disease surveillance is warranted to verify potential clinical consequences of these findings.
Supporting Information
Frequencies of nasopharyngeal carriage of individual S. pneumoniae serotypes in children and parents before, 3 and 4.5 years after PCV-7 implementation.
(DOCX)
Acknowledgments
We wish to thank all the members of the research team, the laboratory staff and the cooperating institutes for their dedication to the projects. Most of all, we are indebted to all the participating children and their families.
Footnotes
Competing Interests: The authors have read the journal's policy and have the following conflicts: RHV has received research support from GlaxoSmithKline and Pfizer-Wyeth for vaccine studies and consulting fees for GlaxoSmithKline. BD declares to have received consulting fees from Pfizer. EAMS has received unrestricted grant support for research from Pfizer-Wyeth and Baxter, consulting fees for Pfizer-Wyeth and GlaxoSmithKline, lecturing fees from Pfizer-Wyeth and GlaxoSmithKline and grant support for vaccine studies from Pfizer-Wyeth and GlaxoSmithKline. All other authors have declared that no competing interests exist. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Funding: This work was supported by the Dutch Ministry of Health the Netherlands. Grant support for pneumococcal surveillance and serotyping was provided by Wyeth-Pfizer Vaccines (grant number WS847078/GIPIHP_RG_20101022T1552, 0887X1-4598). Both funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines. 2006;5:651–667. doi: 10.1586/14760584.5.5.651. [DOI] [PubMed] [Google Scholar]
- 2.Spijkerman J, van Gils EJ, Veenhoven RH, Hak E, Yzerman EP, et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis. 2011;17:584–591. doi: 10.3201/eid1704101115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–154. doi: 10.1016/S1473-3099(04)00938-7. [DOI] [PubMed] [Google Scholar]
- 4.Grijalva CG, Griffin MR. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Rev Vaccines. 2008;7:83–95. doi: 10.1586/14760584.7.1.83. [DOI] [PubMed] [Google Scholar]
- 5.Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines. 2009;8:1351–1364. doi: 10.1586/erv.09.78. [DOI] [PubMed] [Google Scholar]
- 6.Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet. 2004;363:1871–1872. doi: 10.1016/S0140-6736(04)16357-5. [DOI] [PubMed] [Google Scholar]
- 7.Kwambana BA, Barer MR, Bottomley C, Adegbola RA, Antonio M. Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants. BMC Infect Dis. 2011;11:175. doi: 10.1186/1471-2334-11-175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Regev-Yochay G, Dagan R, Raz M, Carmeli Y, Shainberg B, et al. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA. 2004;292:716–720. doi: 10.1001/jama.292.6.716. [DOI] [PubMed] [Google Scholar]
- 9.Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403–409. doi: 10.1056/NEJM200102083440602. [DOI] [PubMed] [Google Scholar]
- 10.Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis. 2003;37:1155–1164. doi: 10.1086/378744. [DOI] [PubMed] [Google Scholar]
- 11.Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet. 2003;361:2189–2195. doi: 10.1016/S0140-6736(03)13772-5. [DOI] [PubMed] [Google Scholar]
- 12.Enright MC, McKenzie H. Moraxella (Branhamella) catarrhalis–clinical and molecular aspects of a rediscovered pathogen. J Med Microbiol. 1997;46:360–371. doi: 10.1099/00222615-46-5-360. [DOI] [PubMed] [Google Scholar]
- 13.Murphy TF, Faden H, Bakaletz LO, Kyd JM, Forsgren A, et al. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J. 2009;28:43–48. doi: 10.1097/INF.0b013e318184dba2. [DOI] [PubMed] [Google Scholar]
- 14.Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751–762. doi: 10.1016/S1473-3099(05)70295-4. [DOI] [PubMed] [Google Scholar]
- 15.van Gils EJ, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, et al. Effect of Seven-Valent Pneumococcal Conjugate Vaccine on Staphylococcus aureus Colonisation in a Randomised Controlled Trial. PLoS One. 2011;6:e20229. doi: 10.1371/journal.pone.0020229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Hill PC, Townend J, Antonio M, Akisanya B, Ebruke C, et al. Transmission of Streptococcus pneumoniae in rural Gambian villages: a longitudinal study. Clin Infect Dis. 2010;50:1468–1476. doi: 10.1086/652443. [DOI] [PubMed] [Google Scholar]
- 17.Jacoby P, Carville KS, Hall G, Riley TV, Bowman J, et al. Crowding and other strong predictors of upper respiratory tract carriage of otitis media-related bacteria in Australian Aboriginal and non-Aboriginal children. Pediatr Infect Dis J. 2011;30:480–485. doi: 10.1097/INF.0b013e318217dc6e. [DOI] [PubMed] [Google Scholar]
- 18.van Lier EA, Oomen PJ, Oostenbrug MW, Zwakhals SL, Drijfhout IH, et al. [High vaccination coverage of the National Immunization Programme in the Netherlands]. Ned Tijdschr Geneeskd. 2009;153:950–957. [PubMed] [Google Scholar]
- 19.van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009;302:159–167. doi: 10.1001/jama.2009.975. [DOI] [PubMed] [Google Scholar]
- 20.O'Brien KL, Nohynek H. Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J. 2003;22:e1–11. doi: 10.1097/01.inf.0000049347.42983.77. [DOI] [PubMed] [Google Scholar]
- 21.Watt JP, O'Brien KL, Katz S, Bronsdon MA, Elliott J, et al. Nasopharyngeal versus oropharyngeal sampling for detection of pneumococcal carriage in adults. J Clin Microbiol. 2004;42:4974–4976. doi: 10.1128/JCM.42.11.4974-4976.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Shrestha NK, Tuohy MJ, Hall GS, Isada CM, Procop GW. Rapid identification of Staphylococcus aureus and the mecA gene from BacT/ALERT blood culture bottles by using the LightCycler system. J Clin Microbiol. 2002;40:2659–2661. doi: 10.1128/JCM.40.7.2659-2661.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008;8:785–795. doi: 10.1016/S1473-3099(08)70281-0. [DOI] [PubMed] [Google Scholar]
- 24.Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, et al. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae–and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization–in HIV-Infected and HIV-uninfected children. J Infect Dis. 2007;196:1662–1666. doi: 10.1086/522164. [DOI] [PubMed] [Google Scholar]
- 25.McNally LM, Jeena PM, Gajee K, Sturm AW, Tomkins AM, et al. Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. J Infect Dis. 2006;194:385–390. doi: 10.1086/505076. [DOI] [PubMed] [Google Scholar]
- 26.Cohen R, Levy C, Thollot F, de La Rocque F, Koskas M, et al. Pneumococcal conjugate vaccine does not influence Staphylococcus aureus carriage in young children with acute otitis media. Clin Infect Dis. 2007;45:1583–1587. doi: 10.1086/523734. [DOI] [PubMed] [Google Scholar]
- 27.Lee GM, Huang SS, Rifas-Shiman SL, Hinrichsen VL, Pelton SI, et al. Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era. BMC Infect Dis. 2009;9:110. doi: 10.1186/1471-2334-9-110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Regev-Yochay G, Bogaert D, Malley R, Hermans PW, Veenhoven RH, et al. Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children? Clin Infect Dis. 2008;47:289–291. doi: 10.1086/589573. [DOI] [PubMed] [Google Scholar]
- 29.Regev-Yochay G, Lipsitch M, Basset A, Rubinstein E, Dagan R, et al. The pneumococcal pilus predicts the absence of Staphylococcus aureus co-colonization in pneumococcal carriers. Clin Infect Dis. 2009;48:760–763. doi: 10.1086/597040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Lebon A, Labout JA, Verbrugh HA, Jaddoe VW, Hofman A, et al. Dynamics and determinants of Staphylococcus aureus carriage in infancy: the Generation R Study. J Clin Microbiol. 2008;46:3517–3521. doi: 10.1128/JCM.00641-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.von Eijff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344:11–16. doi: 10.1056/NEJM200101043440102. [DOI] [PubMed] [Google Scholar]
- 32.Frederiksen MS, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, et al. Changing epidemiology of pediatric Staphylococcus aureus bacteremia in Denmark from 1971 through 2000. Pediatr Infect Dis J. 2007;26:398–405. doi: 10.1097/01.inf.0000261112.53035.4c. [DOI] [PubMed] [Google Scholar]
- 33.Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis. 2009;49:65–71. doi: 10.1086/599348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Ray GT, Suaya JA, Baxter R. Trends and Characteristics of Culture-Confirmed Staphylococcus aureus Infections in a Large U.S. Integrated Health Care Organization. J Clin Microbiol. 2012. [DOI] [PMC free article] [PubMed]
- 35.Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA. 2010;304:2161–2169. doi: 10.1001/jama.2010.1651. [DOI] [PubMed] [Google Scholar]
- 36.Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics. 2006;117:1823–1829. doi: 10.1542/peds.2005-1983. [DOI] [PubMed] [Google Scholar]
- 37.van Gils EJ, Veenhoven RH, Rodenburg GD, Hak E, Sanders EA. Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial. Vaccine. 2011. [DOI] [PubMed]
- 38.Margolis E, Yates A, Levin BR. The ecology of nasal colonization of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus: the role of competition and interactions with host's immune response. BMC Microbiol. 2010;10:59. doi: 10.1186/1471-2180-10-59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Flasche S, van Hoek AJ, Sheasby E, Waight P, Andrews N, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 2011;8:e1001017. doi: 10.1371/journal.pmed.1001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine. 2010;29:283–288. doi: 10.1016/j.vaccine.2010.10.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der LM, et al. Rapid pneumococcal evolution in response to clinical interventions. Science. 2011;331:430–434. doi: 10.1126/science.1198545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008;14:1722–1730. doi: 10.3201/eid1411.070467. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Frequencies of nasopharyngeal carriage of individual S. pneumoniae serotypes in children and parents before, 3 and 4.5 years after PCV-7 implementation.
(DOCX)